Bipar Sciences, Inc.
Records under this name other than patents Bipar Sciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Bipar Sciences, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,732,491 | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents Lapsed on the fee record Ended Jun 8, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jun 8, 2018 | From the USPTO record |
| US 6,169,104 | Di-aryl ethers and their derivatives as anti-cancer agents Term ended Term ended Mar 25, 2018 · From the USPTO record | Term ended | Term ended Mar 25, 2018 | From the USPTO record |
| US 7,538,252 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof Lapsed on the fee record Ended May 26, 2017 · From the USPTO record | Lapsed on the fee record | Ended May 26, 2017 | From the USPTO record |
| US 8,377,985 | Treatment of cancer Lapsed on the fee record Ended Feb 19, 2017 · From the USPTO record | Lapsed on the fee record | Ended Feb 19, 2017 | From the USPTO record |
| US 7,405,227 | Treatment of cancer Lapsed on the fee record Ended Jul 29, 2016 · From the USPTO record | Lapsed on the fee record | Ended Jul 29, 2016 | From the USPTO record |
| US 8,143,447 | Treatment of cancer Lapsed on the fee record Ended Mar 27, 2016 · From the USPTO record | Lapsed on the fee record | Ended Mar 27, 2016 | From the USPTO record |
| US 7,994,222 | Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds Lapsed on the fee record Ended Aug 9, 2015 · From the USPTO record | Lapsed on the fee record | Ended Aug 9, 2015 | From the USPTO record |